Goldman Sachs Group Inc Nuvectis Pharma, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 45,163 shares of NVCT stock, worth $271,881. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,163Holding current value
$271,881% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding NVCT
# of Institutions
54Shares Held
3.62MCall Options Held
97.7KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA699KShares$4.21 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Iridian Asset Management LLC406KShares$2.44 Million1.02% of portfolio
-
Baldwin Brothers LLC350KShares$2.11 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA326KShares$1.96 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $88.1M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...